<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04207697</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-BEL-2019-01</org_study_id>
    <nct_id>NCT04207697</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety and Effectiveness of Beltavac® Polymerized With Cat Dander</brief_title>
  <official_title>Study to Assess the Safety and Effectiveness of Beltavac® Polymerized With Cat Dander</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Probelte Pharma S.L.U.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Probelte Pharma S.L.U.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-interventional Study to Assess the Safety and Effectiveness Profile of a SCIT Therapy&#xD;
      With Beltavac® Polymerized With Cat Dander in allergic patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective open multi-centre non-interventional study assess the safety and&#xD;
      effectiveness profile of the subcutaneous allergen-specific immunotherapy with Beltavac®&#xD;
      Polymerized with cat dander allergic patients (children and adults) in routine medical care.&#xD;
      Patients receive a rush schedule administration every month for a year. They attend at least&#xD;
      5 study visits to inform about the adverse reactions, the self reported symptoms and the&#xD;
      medication intake.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Numbers of treatment-related local and systemic reactions</measure>
    <time_frame>12 months</time_frame>
    <description>Number of adverse reactions occurred during the treatment period and classified according to the WAO standards</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Combined Symptom and Medication Score of Rhinoconjunctivitis</measure>
    <time_frame>12 months</time_frame>
    <description>The score will be calculated as a sum of the symptoms score (0-3) and medication score (0-3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined Symptom and Medication Score of Asthma</measure>
    <time_frame>12 months</time_frame>
    <description>The score will be calculated as a sum of the symptoms score (0-3) and medication score (0-3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analogue Scale Score</measure>
    <time_frame>12 months</time_frame>
    <description>Psycometric scale that assesses the global allergic disease discomfort. It is a 10 cm line representing severity from 0:&quot;no symptoms&quot; to 10 &quot;highest level of symptoms&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgE and IgG4 specific quantification</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>IgE and IgG4 quantification in serum at baseline, 6 and 12 months</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Rhinoconjunctivitis With or Without Allergic Asthma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Beltavac® Polymerized with cat dander</intervention_name>
    <description>Adminstration of Beltavac® Polymerized with cat dander according to the routine clinical practice</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients aged 12 years or older who suffer from allergic rhinoconjunctivitis caused by cat&#xD;
        dander&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of the age of 12 years and older suffering from a clinically relevant cat&#xD;
             dander induced allergic rhinitis or rhinoconjunctivitis associated with or not with&#xD;
             asthma&#xD;
&#xD;
          -  Positive skin testing&#xD;
&#xD;
          -  Positive Serum-Specific IgE determination&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients suffering from acute or chronic infections or inflammations&#xD;
&#xD;
          -  Patients suffering from uncontrolled asthma&#xD;
&#xD;
          -  Patients with a known autoimmune disease&#xD;
&#xD;
          -  Patients with active malignant disease&#xD;
&#xD;
          -  Patients requiring beta-blockers&#xD;
&#xD;
          -  Patients having any contraindication for the use of adrenaline&#xD;
&#xD;
          -  Patients with previous immunotherapy with this allergen or another allergen with&#xD;
             cross-reaction&#xD;
&#xD;
          -  Patients with immunotherapy treatment at the time of inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolina Mérida</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Cecilio Universitary Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Inmaculada Buendía Jiménez, DVM</last_name>
    <phone>+34 968 858577</phone>
    <email>inmaculadabuendia@probeltepharma.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Campus de la Salud University Hospital</name>
      <address>
        <city>Granada</city>
        <state>Andalucía</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolina Mérida Fernández, DM</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ciudad de Jaen Hospital</name>
      <address>
        <city>Jaén</city>
        <state>Andalucía</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blanca Saenz de San Pedro Morera, DM</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Quirón Campo de Gibraltar Hospital</name>
      <address>
        <city>Palmones</city>
        <state>Cádiz</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio García</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Quirón Malaga Hospital</name>
      <address>
        <city>Málaga</city>
        <state>Malaga</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfonso Miranda</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Al-lergo Centre Clinic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfons Malet i Casajuana, DM</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bellvitge University Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ramón Lleonart Bellfill, DM</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alergogranada</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Mayorgas</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 19, 2019</study_first_submitted>
  <study_first_submitted_qc>December 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2019</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

